Routine ketorolac at oocyte retrieval decreases postoperative narcotic use by more than 50%

Featured Article

VOLUME 2, ISSUE 2, P156-160, JUNE 01, 2021


Emily A. Seidler, M.D., Denis A. Vaughan, M.D., Angela Q. Leung, M.D., Denny Sakkas, Ph.D., David A. Ryley, M.D., Alan S. Penzias, M.D.



To study the impact of routine ketorolac administration during oocyte retrieval on the proportion of patients who require postoperative narcotics for analgesia.


Retrospective cohort study.


Single, university-affiliated infertility clinic.


All women undergoing oocyte retrieval between July and November 2016 (non-ketorolac group [NKG]; n = 826) and April-August 2017 (ketorolac group, KG; n = 1780).


A single 30 mg intravenous dose of ketorolac was administered after the oocyte retrieval procedure.

Main outcome measure(s)

The number of patients who required postoperative narcotic analgesia, postoperative complication rate, and fresh embryo transfer pregnancy outcomes were examined.


In the KG, we found a significant decrease in the patients who required narcotics after oocyte retrieval compared with the NKG (12% KG vs. 25.5% NKG). We found no significant change in the clinical pregnancy rate (CPR) resulting from fresh embryo transfer after our intervention (NKG CPR 32.6%, KG CPR 32.4%). Furthermore, there was no increase in postoperative bleeding complications in the KG.


Routine use of ketorolac at the time of oocyte retrieval may decrease the rate of postoperative opioid use without adversely impacting pregnancy and complication rates.

Please sign in or register for FREE

Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.